

THINQ Pharma- CRO Ltd

Chemwatch: 16627 Version No: 8.1.1.1 Safety Data Sheet Chemwatch Hazard Alert Code: 2

Issue Date: 25/03/2015 Print Date: 16/04/2015 Initial Date: Not Available L.GHS.IND.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

BENZO	OCAINE																			
benzoca	caine																			
4-amino Parathe anaesth	iobenzoic a iesin Topca ihetic/ anes	acid, ethy ain, Topo sthetic	thyl ester, ocaine, be	er, Aetho benzoic	noform A ic acid, p	America p-amino	aine An o-, ethyl	aesthes I ester, e	sin Anes ethyl 4-a	sthesin aminobe	Anestho enzoate	ne Kelof ethyl p-a	orm, C iminob	9-H11-lenzoate	N-O2, N e, p-amir	IH2C6	H4CO20 zoic acid,	C2H5, I , ethyl e	Norcair ester, to	n Orthe ppical
ENVIR	CONMENT	TALLY H	HAZARD	RDOUS	S SUBS	STANC	E. SOL	ID NO	S (cor	ntaine h	AD7000	no)								
C9H11N							10000000		.0. (00)	ilidii i3 D	CHZUCA	ne)								
Not Ava	ailable																			
94-09-7	7											+								
94-09-7	7																			
benzo 4-amir Parath anaesi ENVIF C9H11	1	caine nobenzoic nesin Topca thetic/ ane: RONMENTINO2 ailable	caine nobenzoic acid, et nobenzoic acid, et nesin Topcain, To thetic/ anesthetic RONMENTALLY NO2 ailable	caine nobenzoic acid, ethyl est nobenzoic acid, ethyl est nesin Topcain, Topcaine, thetic/ anesthetic RONMENTALLY HAZAF NO2 ailable	caine nobenzoic acid, ethyl ester, Aeth lesin Topcain, Topcaine, benzoi thetic/ anesthetic RONMENTALLY HAZARDOUS NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform lesin Topcain, Topcaine, benzoic acid, thetic/ anesthetic RONMENTALLY HAZARDOUS SUB NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americ nesin Topcain, Topcaine, benzoic acid, p-amin thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANC NO2	caine nobenzoic acid, ethyl ester, Aethoform Americaine Ar lesin Topcain, Topcaine, benzoic acid, p-amino-, ethy thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOL NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesther nesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID. N.C. NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Ane lesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-; thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (col NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin nesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobe thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains b NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID. N.O.S. (contains benzocail) NO2	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Kelofi lesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-a thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C nestin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminob thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11- lesin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, N nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, N nestin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate, p-ami netic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6 nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6 nestin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate, p-aminoben thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO20 nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO20 nestin Topcaine, Denzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate, p-aminobenzoic acid netic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO2C2H5, nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO2C2H5, nestin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate, p-aminobenzoic acid, ethyl e thetic/ anesthetic RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable	caine nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO2C2H5, Norcair nobenzoic acid, ethyl ester, Aethoform Americaine Anaesthesin Anesthesin Anesthone Keloform, C9-H11-N-O2, NH2C6H4CO2C2H5, Norcair nestin Topcain, Topcaine, benzoic acid, p-amino-, ethyl ester, ethyl 4-aminobenzoate, ethyl p-aminobenzoate, p-aminobenzoic acid, ethyl ester, to RONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine) NO2 ailable

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Reagent.
	Local anaesthetic (lozenges, ointments, creams, suppositories)

Details of the manufacturer/importer

Registered company name	THINQ Pharma- CRO Ltd
Address	THINQ House, Ground floor, G-1, Plot No. A-30, Road No. 10, MIDC, Wagle Estate, Thane (W)-400604. India
Telephone	+91-22-25816800
Fax	+91-22-25833325
Website	www.thinqcro.com
Email	enquiry@thinqcro.com

Emergency telephone number

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

CHEMWATCH HAZARD RATINGS

Classes Limi	Min	Max	r !
Flammability	1		
Toxicity	0		
Body Contact	2		0 = Minimum
Reactivity	1		1 = Low 2 = Moderate
Chronic	2		3 = High 4 = Extreme



CANADIAN WHMIS SYMBOLS



Issue Date: 25/03/2015 Print Date: 16/04/2015

3, Acute Aquatic Hazard Category 1

Label elements

GHS label elements







	Notice and State of S	
Hazard state	ment(s)	
	H315	Causes skin irritation
22222	H319	Causes serious eye irritation
THE PERSON NAMED IN	H317	May cause an allergic skin reaction
	H341	Suspected of causing genetic defects
	H335	May cause respiratory irritation
	H400	Very toxic to aquatic life

SIGNAL WORD WARNING

Supplementary statement(s)

Not Applicable

CLP classification (additional)

Not Applicable

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.	
P271	Use only outdoors or in a well-ventilated area.	
P280	Wear protective gloves/protective clothing/eye protection/face protection.	
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.	
P273	Avoid release to the environment.	
P272	Contaminated work clothing should not be allowed out of the workplace.	

Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/attention.	
P302+P352	IF ON SKIN: Wash with plenty of water and soap	
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if p	present and easy to do. Continue rinsing.
P312	Call a POISON CENTER/doctor/physician/first aider/if you feel unwell.	
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.	minutage as
P337+P313	If eye irritation persists: Get medical advice/attention.	
P362+P364	Take off contaminated clothing and wash it before reuse.	
P391	Collect spillage.	mathematic femality of the latest a
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.	

Precautionary statement(s) Storage

P	405	Store locked up.	
P403+F	233	Store in a well-ventilated place. Keep container tightly closed.	

Precautionary statement(s) Disposal

Dispose of contents/container to authorised chemical landfill or if organic to high temperature incineration

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

CAS No	%[weight]	Name	GHS Classification
94-09-7	>98	benzocaine	Skin Corrosion/Irritation Category 2, Eye Irritation Category 2A, Skin Sensitizer Category 1, Germ Cell Mutagen Category 2, STOT - SE (Resp. Irr.) Category 3, Acute Aquatic Hazard Category 1; H315, H319, H317, H341, H335, H400

Mixtures

See section above for composition of Substances

SECTION 4 FIRST AID MEASURES

Description of first aid measures

If this product comes in contact with the eyes: Eye Contact

Wash out immediately with fresh running water.

Issue Date: 25/03/2015 Print Date: 16/04/2015

	 Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor, without delay.
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Indication of any immediate medical attention and special treatment needed

When systemic reaction to local anaesthetic occurs, steps should be taken to maintain circulation and respiration and control convulsions. A clear airway should be established and oxygen given together with assisted ventilation if necessary. Circulation should be maintained with plasma infusion (or suitable electrolytes). Vasopressors such as ephedrine, metaraminol and methoxamine have been suggested in marked hypotension although their use is accompanied by the risk of CNS excitement. (Vasopressors should not be given in patients receiving oxytocic drugs.) Convulsions may be controlled by the use of diazepam or short acting barbiturates such as thiopentone sodium. It should be remembered that anticonvulsant treatment may also depress respiration. A short-acting neuromuscular blocking agent, together with endotracheal intubation and artificial respiration has been used when convulsions persist.

Methaemoglobinaemia may be treated by intravenous administration of a 1% solution of methylene blue.

MARTINDALE; The Extra Pharmacopoeia, 29th Edition

Local anaesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient's legs and positioning the patient on the left side will help decrease blood pressure.

Metabolism of amide-type anaesthetics occurs in the liver and in some cases in the kidney. Because these undergo extensive and rapid hepatic metabolism, only about 1/3 of an oral dose reaches the systemic circulation.

SECTION 5 FIREFIGHTIN	G MEASURES
Extinguishing media	
	 Foam. Dry chemical powder. BCF (where regulations permit). Carbon dioxide. Water spray or fog - Large fires only.
Special hazards arising fro	m the substrate or mixture
Fire Incompatibility	r Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
Advice for firefighters	
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water courses. Use water delivered as a fine spray to control fire and cool adjacent area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	 Combustible solid which burns but propagates flame with difficulty; it is estimated that most organic dusts are combustible (circa 70%) - according to the circumstances under which the combustion process occurs, such materials may cause fires and / or dust explosions. Organic powders when finely divided over a range of concentrations regardless of particulate size or shape and suspended in air or some other oxidizing medium may form explosive dust-air mixtures and result in a fire or dust explosion (including secondary explosions). Avoid generating dust, particularly clouds of dust in a confined or unvenibited space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust (420 micron or less) may burn rapidly and fiercely if ignited - particles exceeding this limit will generally not form flammable dust clouds; once initiated, however, larger particles up to 1400 microns diameter will contribute to the propagation of an explosion. In the same way as gases and vapours, dusts in the form of a cloud are only ignitable over a range of concentrations; in principle, the concepts of lower explosive limit (LEL) and upper explosive limit (UEL) are applicable to dust clouds but only the LEL is of practical use; - this is because of the inherent difficulty of achieving homogeneous dust clouds at high temperatures (for dusts the LEL is often called the "Minimum Explosible Concentration", MEC). When processed with flammable liquids/vapors/mists,ignitable (hybrid) mixtures may be formed with combustible dusts. Ignitable mixtures will increase the pure dust in air mixture. The Lower Explosive Limit (LEL) of the vapour/dust mixture will be lower than the individual LELs for the vapors/mists or dusts. A dust explosion may release of large quantities of gaseous products; this

► Dry dust can be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.

Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.

A sudden release of statically charged materials from storage or process equipment, particularly at elevated temperatures and/ or pressure, may result in

► Build-up of electrostatic charge may be prevented by bonding and grounding.

All movable parts coming in contact with this material should have a speed of less than 1-meter/sec.

Issue Date: 25/03/2015 Print Date: 16/04/2015

ignition especially in the absence of an apparent ignition source.

- One important effect of the particulate nature of powders is that the surface area and surface structure (and often moisture content) can vary widely from sample to sample, depending of how the powder was manufactured and handled; this means that it is virtually impossible to use flammability data published in the literature for dusts (in contrast to that published for gases and vapours).
- Autoignition temperatures are often quoted for dust clouds (minimum ignition temperature (MIT)) and dust layers (layer ignition temperature (LIT)); LIT generally falls as the thickness of the layer increases.

Combustion products include; carbon monoxide (CO) carbon dioxide (CO2) nitrogen oxides (NOx) other pyrolysis products typical of burning organic material

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Environmental hazard - contain spillage

- Clean up waste regularly and abnormal spills immediately. Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.

Minor Spills

- Use dry clean up procedures and avoid generating dust.
 Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- ▶ Place in suitable containers for disposal.

Environmental hazard - contain spillage.

Moderate hazard

- ► CAUTION: Advise personnel in area.
- Alert Emergency Services and tell them location and nature of hazard.
- Control personal contact by wearing protective clothing.
- Prevent, by any means available, spillage from entering drains or water courses.

Recover product wherever possible.

- F DRY: Use dry clean up procedures and avoid generating dust. Collect residues and place in sealed plastic bags or other containers for disposal, IF WET: Vacuum/shovel up and place in labelled containers for disposal.
- ALWAYS: Wash area down with large amounts of water and prevent runoff into drains.
- If contamination of drains or waterways occurs, advise Emergency Services.

Personal Protective Equipment advice is contained in Section 8 of the MSDS.

SECTION 7 HANDLING AND STORAGE

Major Spills

Precautions for safe handling

- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- DO NOT enter confined spaces until atmosphere has been checked.
- DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
- When handling, DO NOT eat, drink or smoke.
- Keep containers securely sealed when not in use.
- Avoid physical damage to containers.
- Always wash hands with soap and water after handling.
- Work clothes should be laundered separately. Launder contaminated clothing before re-use.
- Use good occupational work practice.
- Observe manufacturer's storage and handling recommendations contained within this MSDS.
- Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
- Organic powders when finely divided over a range of concentrations regardless of particulate size or shape and suspended in air or some other oxidizing medium may form explosive dust-air mixtures and result in a fire or dust explosion (including secondary explosions)
- Minimise airborne dust and eliminate all ignition sources. Keep away from heat, hot surfaces, sparks, and flame.
- Safe handling Establish good housekeeping practices.
 - Remove dust accumulations on a regular basis by vacuuming or gentle sweeping to avoid creating dust clouds.
 - Use continuous suction at points of dust generation to capture and minimise the accumulation of dusts. Particular attention should be given to overhead and hidden horizontal surfaces to minimise the probability of a "secondary" explosion. According to NFPA Standard 654, dust layers 1/32 in.(0.8 mm) thick can be sufficient to warrant immediate cleaning of the area.
 - Do not use air hoses for cleaning.
 - Minimise dry sweeping to avoid generation of dust clouds. Vacuum dust-accumulating surfaces and remove to a chemical disposal area. Vacuums with explosion-proof motors should be used.

 - Control sources of static electricity. Dusts or their packages may accumulate static charges, and static discharge can be a source of ignition.
 Solids handling systems must be designed in accordance with applicable standards (e.g. NFPA including 654 and 77) and other national guidance.
 - Do not empty directly into flammable solvents or in the presence of flammable vapors.
 - The operator, the packaging container and all equipment must be grounded with electrical bonding and grounding systems. Plastic bags and plastics cannot be grounded, and antistatic bags do not completely protect against development of static charges.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.

- Do NOT cut, drill, grind or weld such containers.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

- Store in original containers. Keep containers securely sealed.
- Store in a cool, dry area protected from environmental extremes.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this MSDS.

For major quantities:

Other information

► Consider storage in bunded areas - ensure storage areas are isolated from sources of community water (including stormwater, ground water, lakes and

Issue Date: 25/03/2015 Print Date: 16/04/2015

streams)

Finance that accidental discharge to air or water is the subject of a contingency disaster management plan; this may require consultation with local

Conditions for safe storage, including any incompatibilities

Suitable container

- Glass container is suitable for laboratory quantities
- Polyethylene or polypropylene container
- ▶ Check all containers are clearly labelled and free from leaks.

Storage incompatibility

Avoid reaction with oxidising agents

PACKAGE MATERIAL INCOMPATIBILITIES

Not Available

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Not Available

EMERGENCY LIMITS

Ingredient	Material name	TEEL-1		
BENZOCAINE		ICCL-I	TEEL-2	TEEL-3
BENZOCAINE	Not Available	Not Available	Not Available	Not Available
Ingredient	Original IDLH		Revised IDLH	
benzocaine	Net A II-LI		Kevised IDLH	
ron acodano	Not Available		Not Available	

MATERIAL DATA

It is the goal of the ACGIH (and other Agencies) to recommend TLVs (or their equivalent) for all substances for which there is evidence of health effects at airborne concentrations encountered in

At this time no TLV has been established, even though this material may produce adverse health effects (as evidenced in animal experiments or clinical experience). Airborne concentrations must be maintained as low as is practically possible and occupational exposure must be kept to a minimum.

NOTE: The ACGIH occupational exposure standard for Particles Not Otherwise Specified (P.N.O.S) does NOT apply.

Sensory irritants are chemicals that produce temporary and undesirable side-effects on the eyes, nose or throat. Historically occupational exposure standards for these irritants have been based on observation of workers' responses to various airborne concentrations. Present day expectations require that nearly every individual should be protected against even minor sensory irritation and exposure standards are established using uncertainty factors or safety factors of 5 to 10 or more. On occasion animal no-observable-effect-levels (NOEL) are used to determine these limits where human results are unavailable. An additional approach, typically used by the TLV committee (USA) in determining respiratory standards for this group of chemicals, has been to assign ceiling values (TLV C) to rapidly acting irritants and to assign short-term exposure limits (TLV STELs) when the weight of evidence from irritation, bioaccumulation and other endpoints combine to warrant such a limit. In contrast the MAK Commission (Germany) uses a five-category system based on intensive odour, local irritation, and elimination half-life. However this system is being replaced to be consistent with the European Union (EU) Scientific Committee for Occupational Exposure Limits (SCOEL); this is more closely allied to that of the USA. OSHA (USA) concluded that exposure to sensory irritants can:

- r cause inflammation
- rease increased susceptibility to other irritants and infectious agents
- lead to permanent injury or dysfunction
- permit greater absorption of hazardous substances and
- r acclimate the worker to the irritant warning properties of these substances thus increasing the risk of overexposure.

Airborne particulate or vapour must be kept to levels as low as is practicably achievable given access to modern engineering controls and monitoring hardware. Biologically active compounds may produce idiosyncratic effects which are entirely unpredictable on the basis of literature searches and prior clinical experience (both recent and past).

Exposure controls

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation. HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours. Barrier protection or laminar flow cabinets should be considered for laboratory scale handling. A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg. When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/containment technology. Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies. Appropriate engineering Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required. Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant. Type of Contaminant: Air Speed: solvent, vapours, etc. evaporating from tank (in still air) 0.25-0.5 m/s (50-100 f/min.)

Issue Date: 25/03/2015 Print Date: 16/04/2015

f/min.)

0.5-1 m/s (100-200 aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into f/min.) zone of active generation) 1-2.5 m/s (200-500 direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)

Within each range the appropriate value depends on:

	Upper end of the range	
Lower end of the range 1: Room air currents minimal or favourable to capture	1: Disturbing room air currents	
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity	
3; Intermittent, low production.	3: High production, heavy use	
4: Large hood or large air mass in motion	4: Small hood-local control only	

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of:

10; high efficiency particulate (HEPA) filters or cartridges

10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.

25-50; a full face-piece negative pressure respirator with HEPA filters

50-100; tight-fitting, full face-piece HEPA PAPR

100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode.

Personal protection











When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

Chemical goggles.

Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.

 Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate imitants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Skin protection

Eve and face protection

See Hand protection below

NOTE:

▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.

Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- r frequency and duration of contact,
- chemical resistance of glove material,
- ► glove thickness and

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

Hands/feet protection

- ▶ When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes
- according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS
- 2161.10.1 or national equivalent) is recommended. Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.

Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is

- Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Change gloves frequently and when contaminated, punctured or tom.
- Wash hands immediately after removing gloves.
- ► Protective shoe covers. [AS/NZS 2210]
- Head covering.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.

	polychloroprene, initrile rubber. biutyl rubber. fluorocaoutchouc, polyvinyl chloride, Gloves should be examined for wear and/ or degradation constantly.
Body protection	See Other protection below
Other protection	 For quantities up to 500 grams a laboratory coat may be suitable. For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and c For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers. For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection. Eye wash unit. Ensure there is ready access to an emergency shower. For Emergencies: Vinyl suit
Thermal hazards	Not Available

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the computergenerated selection:

BENZOCAINE Not Available

D2 3 3 3 3	
Material	CPI

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Particulate. (AS/NZS 1716 & 1715, EN 143:000 & 149:001, ANSI Z88 or national equivalent)

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	P1 Air-line*		PAPR-P1
up to 50 x ES	Air-line**	P2	PAPR-P2
up to 100 x ES		P3	-
		Air-line*	2
100+ x ES		Air-line**	PAPR-P3

* - Negative pressure demand ** - Continuous flow

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Odourless white crystalline powder w	ith a slightly bitter numbing taste; insoluble in water. Soluble	e in alcohol, ether, chloroform and dilute acids.
Physical state	Divided Solid	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	88	Viscosity (cSt)	Not Applicable
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	165.21
Flash point (°C)	Not Available	Taste	No.
Evaporation rate	Not Applicable	Explosive properties	Not Available Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not available.	Surface Tension (dyn/cm or mN/m)	Not Applicable
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Negligible
Vapour pressure (kPa)	Negligible	Gas group	Not Available
Solubility in water (g/L)	Immiscible	pH as a solution (1%)	Not Applicable
Vapour density (Air = 1)	Not Applicable	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7		
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur. 		
Possibility of hazardous reactions	See section 7		
Conditions to avoid	See section 7		

Issue Date: 25/03/2015

Print Date: 16/04/2015

Incompatible materials

See section 7

Hazardous decomposition products

See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Inhaled

Ingestion

Skin Contact

Chronic

Legend:

Information on toxicological effects

Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.

Inhalation of local anaesthetics may result in upper respiratory tract effects including burning sensation, stinging, tenderness, swelling, sloughing, tissue necrosis and irritation. Systemic poisoning is characterised by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting and sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness and respiratory depression and arrest. Cardiac arrest may result from cardiovascular collapse. Bradycardia and hypotension may also be produced. Excessive application to mucous membranes has been associated with methaemoglobinaemia producing a cyanosis.

Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

If prior damage to the circulatory or nervous systems has occurred or if kidney damage has been sustained, proper screenings should be conducted on individuals who may be exposed to further risk if handling and use of the material result

Overexposure may result in headache, nausea, dizziness, fatigue and weakness in arms and legs.

Accidental ingestion of the material may be damaging to the health of the individual. Local anaesthetics may produce systemic effects following excessive dosage by any route, Systemic toxicity mainly involves the central nervous system and the cardiovascular system. Central nervous system excitation may be manifested by yawning, restlessness, excitement, tinnitus, nausea and vomiting. Numbness of the tongue and perioral region is an early sign of systemic toxicity. Simultaneous effects on the cardiovascular system may result in myocardial depression and

peripheral vasodilation resulting in hypotension and bradycardia. The substance and/or its metabolites may bind to haemoglobin inhibiting normal uptake of oxygen. This condition, known as "methaemoglobinemia", is a form of

oxygen starvation (anoxia). Symptoms include cyanosis (a bluish discolouration skin and mucous membranes) and breathing difficulties. Symptoms may not be evident until several hours

At about 15% concentration of blood methaemoglobin there is observable cyanosis of the lips, nose and earlobes. Symptoms may be absent although euphoria, after exposure. flushed face and headache are commonly experienced. At 25-40%, cyanosis is marked but little disability occurs other than that produced on physical exertion. At 40-60%, symptoms include weakness, dizziness, lightheadedness, increasingly severe headache, ataxia, rapid shallow respiration, drowsiness, nausea, vomiting, confusion, lethargy and stupor. Above 60% symptoms include dyspnea, respiratory depression, tachycardia or bradycardia, and convulsions. Levels exceeding 70% may be fatal.

The material produces mild skin irritation; evidence exists, or practical experience predicts, that the material either

produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or

roduces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often

characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidemis. Repeated exposure may cause skin cracking, flaking or drying following normal handling and use.

Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.

Topical application of local anaesthetics may produce burning, stinging, tenderness, erythema, excoriation, vesiculation, sloughing and tissue necrosis.

Photosensitivity reactions may produce skin eruptions. Open cuts, abraded or imitated skin should not be exposed to this material

Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

|Benzocaine produces methaemoglobin in the blood of infants exposed to the substance following topical application.|Between 3 and 6% of patients receiving topical application of the substance (in soft paraffin wax carrier) exhibit allergic dermatitis or eczema.

Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis);

temporary impairment of vision and/or other transient eye damage/ulceration may occur. Direct eye contact with local anaesthetics may produce anaesthesia of the eyes and increase the risk of mechanical injury due to foreign bodies, because of loss of sensation. There may also be abnormal drying of the comea, temporary burning sensations, lachrymation, photophobia, chemosis, increased blinking

and conjunctival redness. Systemic exposure may produce atrophy of the optic nerve. Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Strong evidence exists that the substance may cause irreversible but non-lethal mutagenic effects following a single exposure. Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or

of producing a positive response in experimental animals. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

Repeated or prolonged exposure with local anaesthetics may result in hypersensitivity reactions including cutaneous lesions, urticaria, oedema and potentially fatal anaphylactoid reactions. Permanent corneal opacification with visual loss, severe keratitis, scarring or corneal perforation may result from prolonged eye contact. Repeated doses of local anaesthetics may cause significant increases in plasma levels due to the slow accumulation of the drug or its metabolites or to slow metabolic degradation. Tolerance to elevated blood levels varies with the physical condition of the patient.

IRRITATION TOXICITY benzocaine Skin (g.pig): 2% (48h) : mild Oral (rat) LD50; 3042 mg/kg^[2]

1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's msds. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema BENZOCAINE

Issue Date: 25/03/2015 Print Date: 16/04/2015

involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibodymediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the imitating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production.

for p-aminobenzoates (PABA and its derivatives):

PABA (p-aminobenzoic acid; syn: 4-aminobenzoic acid) is a chemical found in the folic acid vitamin and also in several foods including grains, eggs, milk,

PABA is taken by mouth for skin conditions including vitiligo, pemphigus, dermatomyositis, morphea, lymphoblastoma cutis, Peyronie's disease, and scleroderma. PABA is also used to treat infertility in women, arthritis, anaemia), rheumatic fever, constipation, systemic lupus erythematosus (SLE), and headache. It is also used to darken gray hair, prevent hair loss, make skin look younger, and prevent sunburn. PABA and its derivatives is best known as a sunscreen that is applied to the skin. Local anesthetics used in temporary pain relief are often derivatives of PABA (e.g. benzocaine). PABA reportedly enhances the effects of cortisone, oestrogen, and other hormones It prevents accumulation of abnormal fibrous tissue. PABA enables intestinal bacteria to produce folic acid. It functions in the breakdown and utilisation of proteins and in the formation of blood cells.

Human overdose data on PABA or its esters are rare. Most toxicology data are derived from animal experimentation or chronic, large dose therapeutic use. Nausea, vomiting, and abdominal cramps as well as metallic taste are often seen with oral therapy. Ingestions of more than 10 grams per day for days have been necessary to induce symptoms other than local gastrointestinal imitation. Clinical use of PABA at doses of 10 grams per day or more have produced nausea, vomiting, acidosis, pruritus, rash, fever, methaemoglobinaemia and, possibly, hepatitis.

This regime tended to produce a decrease in white cell count (leucopenia) while higher doses produced delirium.

Chronic feeding studies indicate rats are resistant to p-aminobenzoic acid with acute gastroententis and haemorrhage of the small intestine capillaries being involved in any toxic effect. Acute necrosis of the liver occurred in some dogs during feeding trials.

PABA is an essential nutrient for some bacteria and is sometimes called Vitamin B x . However, PABA is not essential for humans and it varies in its activity from other B vitamins. Although humans lack the ability to synthesise folate from PABA, it is often sold, misleadingly, as an essential nutrient. PABA is sometimes included in multi-vitamin preparations; adverse effects from oral doses have not been reported at lower doses.

Derivatives of PABA, have been associated with acute allergic reactions. As sunscreens PABA derivatives have reportedly produced allergic contact dermatitis; although transient this effect may be severe compounding the phototoxicity for which it is applied. PABA or other related substances are also capable of inducing photoallergic reactions or systemic lupus erythematous. In the past, PABA has been widely used as UV filter in sunscreen formulations. However, it has been determined that it increases the risk of DNA damage and risk of skin cancer. Other derivatives of PABA, such as octyl dimethyl PABA (padimate(s) A and O) are more commonly used so their safety has been brought into question as well.

In bioassays designed to examine the potential for PABA contact sensitisation there have been mixed results. One researcher was not able to produce delayed contact hypersensitivities in guinea pigs in the Magnussen Kligman maximisation test, in a modified Draize test or in a single injection adjuvant test. Another, however, produced sensitisation responses in 33% of animals in the maximisation test (5 responders in 15 test animals). Mixed results have been produced in bioassays for photoallergic potential. One study with guinea pigs could not produce evidence supporting this proposition whilst another showed photoallergic and persistent light reactions

Aminobenzoic acid is chemically similar to other drugs that cause photosensitivity reactions in susceptible individuals including thiazides, sulfonamides, sulfonylureas, furosemide, and carbonic anhydrase inhibitors. Cross-reactivity may also occur with benzocaine and p-phenylenediamine. Individuals who have had photosensitivity reactions while taking any of these drugs should not use a sunscreen containing aminobenzoic acid or one of its derivatives (aminobenzoate, menthyl anthranilate, or padimate A or O).

A nitrosamine known as NPABAO (2-ethylhexyl-4-(N-methyl-N-nitrosoamino)benzoate has been found in certain sunscreens containing padimate-O as the active ingredient. Nitrosamines themselves can be carcinogenic; however, at this time it is uncertain whether this nitrosamine is present in sufficient quantities in sunscreens to be of concern.

Padimate O absorbs ultraviolet rays, thereby preventing direct DNA damage by UV-B. However, the thus excited padimate O molecule can then react with DNA and produce indirect DNA damage, similar to the effects of ionizing radiation. A study in 1993 demonstrated the sunlight-induced mutagenicity of Padimate O The photobiological properties of padimate O resemble those of Michler's ketone which is considered photocarcinogenic in rats and mice. These findings suggest that padimate O might also be photocarcinogenic

Sulfonamides (sulfa drugs) are chemically similar to PABA, and their antibacterial activity is due to their ability to interfere with PABA utilization by bacteria. The chemically related 4-aminosalicylic acid, used as as an antibacterial has produced, allergic reactions are recorded in over 5% of adults treated with the sodium salt. Fever, athralgia, lymphadenopathy, and more rarely a syndrome resembling mononucleosis may also occur. Other (apparently) allergic reactions to aminosalicylate include jaundice, liver necrosis, pancreatitis, pulmonary infiltration, encephalitis, nephritis, and renal failure. Skin rashes often occurs after treatment Exfoliative dermatitis is common. The p-aminophenyl group formed during metabolism of aminosalicylate may provoke reaction in hypersensitive individuals (cross-sensitive) to sulfonamides, phenacetin, sulfones and to certain hair-dyes containing related

The material may cause skin imitation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular cedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. Dyspnea, cyanosis recorded.

Acute Toxicity	0	Carcinogenicity	0
Skin Irritation/Corrosion	4	Reproductivity	0
Serious Eye Damage/Irritation	~	STOT - Single Exposure	~
Respiratory or Skin sensitisation	~	STOT - Repeated Exposure	0
Mutagenicity	~	Aspiration Hazard	0

Legend:

Data required to make classification available

— Data available but does not fill the criteria for classification

Data Not Available to make classification

CMR STATUS Not Applicable

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

NOT AVAILABLE						BCF
Ingredient	Endpoint	Test Duration	Effect	Value	Species	
mgrous		Not Available				
benzocaine	Not Available	Not Available	NOLAVAIIABLE			

Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.

Wastes resulting from use of the product must be disposed of on site or at approved waste sites.

DO NOT discharge into sewer or waterways.

Nitrif. inhib.: 30% inhib at 100mg/L

Persistence and degradability

reisistence and de	gradasiiity	Persistence: Air
Ingredient	Persistence: Water/Soil	
benzocaine	HIGH	HIGH

Discoumulative notential

accumulative potential
gredient Bioaccumulation
aine LOW (LogKOW = 1.86)

Mobility in soil

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods

- ► Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible.

Otherwise:

- F If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- Where possible retain label warnings and MSDS and observe all notices pertaining to the product.

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate:

Product / Packaging

disposal

- ► Reduction
- r Reuse
- ► Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate. In most instances the supplier of the material should be consulted.

- DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.

SECTION 14 TRANSPORT INFORMATION

Labels Required



Marine Pollutant



Land transport (UN)

3077		
III		
ENVIRONM	NTALLY HAZARDOUS SUBSTANCE, SOLID, N	.O.S. (contains benzocaine)
No relevant of	ta	
Class	9	
Subrisk	Not Applicable	
	III ENVIRONME No relevant dai Class	III ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N No relevant data Class 9

Special precautions for user

Special provisions 274;331;335;375

Limited quantity 5 kg

Air transport (ICAO-IATA / DGR)

UN number	3077	
Packing group	III	
UN proper shipping name	Environmentally hazardous substance, solid, n.o.s. *	(contains benzocaine)
Environmental hazard	No relevant data	,
	ICAO/IATA Class 9	
Transport hazard class(es)	ICAO / IATA Subrisk Not Applicable	
	ERG Code 9L	
	Special provisions	A97 A158 A179 A197
	Cargo Only Packing Instructions	956
	Cargo Only Maximum Qty / Pack	400 kg
Special precautions for user	Passenger and Cargo Packing Instructions	956
	Passenger and Cargo Maximum Qty / Pack	400 kg
	Passenger and Cargo Limited Quantity Packing In	structions Y956
	Passenger and Cargo Limited Maximum Qty / Pacl	k 30 kg G

Sea transport (IMDG-Code / GGVSee)

UN number	3077	
Packing group	III	
UN proper shipping name	ENVIRONMENTAL	LY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (contains benzocaine)
Environmental hazard	Not Applicable	,
Transport hazard class(es)	IMDG Class	9
	IMDG Subrisk	Not Applicable
	EMS Number	F-A,S-F
Special precautions for user	Special provisions	274 335 966 967
	Limited Quantities	5 kg

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

benzocaine(94-09-7) is found on the following regulatory lists

"International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs"

ECHA SUMMARY

Ingredient	CAS number	Index No	ECHA Dossier	
benzocaine	94-09-7	Not Available	Not Available	

Harmonisation (C&L inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Skin Sens. 1	GHS07, Wng	H317
2	Skin Sens. 1, Acute Tox. 4, Eye Irrit. 2, Aquatic Chronic 2, Skin Irrit. 2, STOT SE 3	, ,	H317, H312, H332, H319, H411, H315, H335, H302

Harmonisation Code 1 = The most prevalent classification. Harmonisation Code 2 = The most severe classification.

tional Inventory	Status		
Australia - AICS	Y		
Canada - DSL	Y		
China - IECSC	Υ		
Europe - EINEC / ELINCS / NLP	Y		
Japan - ENCS	Y		
Korea - KECI	Y		
New Zealand - NZIoC	Y		
Philippines - PICCS	Y		
USA - TSCA	Y		

Chemwatch: 16627 Version No: 8.1.1.1 Page 12 of 12

BENZOCAINE

Issue Date: 25/03/2015 Print Date: 16/04/2015

Legend:

Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at:

www.chemwatch.net

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.